Lariago (Generic Chloroquine Tablets)

© Clearsky Pharmacy
Lariago (Generic Chloroquine Phosphate)

Lariago (Generic Chloroquine Phosphate) is used for the
suppressive treatment and for the treatment of acute
attacks of Malaria due to P. vivax, P.Malariae, P. Ovale, and
susceptible strains of P. Falciparum.
This medicine is also indicated for the treatment of
extraintestinal amebiasis, amoebic hepatitis and abscess,
discoid and systemic lupus erythematosus and rheumatoid
arthritis.
Off-Label indications include the treatment of corona virus
disease 2019 (COVID-19) and severe acute respiratory
syndrome coronavirus2 (SARS-CoV-2) infection.

Lariago Tablets are manufactured by
IPCA Laboratories Limited, India.
(Website: www.ipca.com)

Chloroquine Phosphate Tablets – Brand Names
Chloroquine Phosphate tablets are
available as Aralen, Lariago, Resochin,
Nivaquine, Cadiquin, Emquin, Quinross
DT and Cloquin.

Active Ingredient
The active ingredient contained in Lariago
tablets is Chloroquine Phosphate.
Each tablet contains 250 mg of Chloroquine
Phosphate .

Chemical Structure
The structure of Chloroquine Phosphate is given below:

Uses of Lariago 250mg Tablets
Lariago (Generic Chloroquine tablets) is used for the
suppressive treatment and for acute attacks of malaria due
to P. vivax, P.malariae, P. ovale , and susceptible strains of
P. falciparum.
This medicine is also used for the treatment of
extraintestinal amebiasis, treatment of amoebic hepatitis
and abscess, treatment of discoid and systemic lupus
erythematosus and treatment of rheumatoid arthritis.

Storage Instructions
Lariago (Generic Chloroquine Phosphate
tablets) have to be stored at controlled room
temperature i.e. from 20°C to 25°C (68°F to
77°F) with excursions permitted between 15°
to 30°C (59° to 86°F).
Keep this as well as all other medicines away
from children and pets.

Warnings
Chloroquine Phosphate (Lariago tablets) has been shown to cause
severe hypoglycaemia including loss of consciousness that could be life
threatening in patients treated with and without antidiabetic medications.
Patients treated with chloroquine should be warned about the risk of
hypoglycaemia and the associated clinical signs and symptoms.
Chloroquine has been shown to prolong the QTc interval in some
patients.
Chloroquine should be used with caution in patients with congenital or
documented acquired QT prolongation and/or known risk factors for
prolongation of the QT interval.
In patients receiving Chloroquine therapy cases of cardiomyopathy have
been reported, leading to heart failure, sometimes with fatal outcome.

Warnings
Caution is necessary when giving Avloclor to patients with impaired hepatic function,
particularly when associated with cirrhosis.
Caution is also necessary in patients with porphyria.
A small number of cases of diffuse parenchymal lung disease have been identified in
patients taking chloroquine.
Cases of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have
been identified in patients taking chloroquine alone or in combination with proguanil.
Caution is necessary when giving Lariago tablets to patients with renal disease.
Lariago tablets should be used with care in patients with a history of epilepsy. Potential
risks and benefits should be carefully evaluated before use in subjects on anticonvulsant
therapy or with a history of epilepsy as rare cases of convulsions have been reported in
association with chloroquine.

Warnings
Considerable caution is needed in the use of Chloroquine (Lariago tablets)
for long-term high dosage therapy and such use should only be considered
when no other drug is available. Patients on long-term therapy should also
be monitored for cardiomyopathy.
Irreversible retinal damage and corneal changes may develop during long
term therapy and after the drug has been discontinued. Ophthalmic
examination prior to and at 3 to 6 monthly intervals during use is required
if patients are receiving chloroquine tablets.
Full blood counts should be carried out regularly during extended
treatment as bone marrow suppression may occur rarely. Caution is
required if drugs known to induce blood disorders are used concurrently.

Warnings
The use of Lariago (Generic Chloroquine Phosphate) in
patients with psoriasis may precipitate a severe attack.
Caution is advised in patients with glucose-6-phosphate
dehydrogenase deficiency, as there may be a risk of
haemolysis.
Acute extrapyramidal disorders have been reported during
treatment with Chloroquine, usually disappearing on
discontinuation of treatment and /or on symptomatic
treatment.

Lariago Dosage
➢Prophylaxis Against Chloroquine-Sensitive Plasmodium Species:
Adult Dose: The dosage for prophylaxis is 500 mg administered
once per week on exactly the same day of each week.
➢Treatment of uncomplicated malaria due to chloroquine-
sensitive Plasmodium species: Adult Dose: An initial dose of 1000
mg followed by an additional 500 mg after six to eight hours and
a single dose of 500 mg on each of two consecutive days.
The adult dosage of Lariago tablets (Chloroquine
Phosphate) is given below:

Lariago Dosage
➢Extraintestinal Amebiasis: Adults Dosage: 1000 mg daily for
two days, followed by 500 mg daily for at least two to three
weeks. Treatment is usually combined with an effective
intestinal amebicide.
The dosage of Lariago (Generic Chloroquine Phosphate tablets)
is given below:

Lariago Dosage for Covid-19
➢Chloroquine Tablets Dosage for Covid-19 (Experimental): The
recommended dose of Lariago (Chloroquine Phosphate tablets)
for patients with mild, moderate and severe COVID-19 who have
no Chloroquine contraindications should be treated with
Chloroquine Phosphate at a dose of 500 mg twice per day for 10
days. Please note that this medicine is currently used to treat
Corona virus on a experimental basis only. Please consult your
doctor before taking this or any other medication.
The dosage of Lariago (Generic Chloroquine Phosphate tablets)
is given below:

Contraindications
Lariago is contraindicated in patients with a
hypersensitivity to Chloroquine Phosphate, 4-
aminoquinoline compounds or any other component
of this medication.
Use of Lariago for indications other than acute
malaria is contraindicated in the presence of retinal or
visual field changes of any etiology.

Lariago Side Effects
➢Ocular: Irreversible retinal damage in patients receiving long-term or high-
dosage 4-aminoquinoline therapy; visual disturbances (blurring of vision and
difficulty of focusing or accommodation); nyctalopia; scotomatous vision with
field defects of paracentral, pericentral ring types, and typically temporal
scotomas, e.g., difficulty in reading with words tending to disappear, seeing half
an object, misty vision, and fog before the eyes.
➢ Auditory: Nerve type deafness; tinnitus, reduced hearing in patients with
preexisting auditory damage. Musculoskeletal system: Skeletal muscle
myopathy or neuromyopathy leading to progressive weakness and atrophy of
proximal muscle groups, which may be associated with mild sensory changes,
depression of tendon reflexes and abnormal nerve conduction, have been
noted.

Lariago Side Effects
➢Gastrointestinal system: Anorexia, nausea, vomiting, diarrhea, abdominal
cramps. Skin and appendages: Pleomorphic skin eruptions, skin and mucosal
pigmentary changes; lichen planus-like eruptions, pruritus, photosensitivity and
hair loss and bleaching of hair pigment.
➢ Hematologic system: Rarely, aplastic anemia, reversible agranulocytosis,
thrombocytopenia and neutropenia.
➢ Central Nervous system: Convulsive seizures. Mild and transient headache.
Neuropsychiatric changes including psychosis, delirium, personality changes
and depression.
➢ Cardiovascular system: Rarely, hypotension, electrocardiographic change
(particularly, inversion or depression of the T-wave with widening of the QRS
complex), and cardiomyopathy.

Lariago Overdose
Chloroquine is very rapidly and completely absorbed after ingestion.
Toxic doses of chloroquine can be fatal. As little as 1000 mg may be fatal
in children.
Toxic symptoms can occur within minutes. These consist of headache,
drowsiness, visual disturbances, nausea and vomiting, cardiovascular
collapse, shock and convulsions followed by sudden and early
respiratory and cardiac arrest. Hypokalemia has been observed with
arrhythmias in cases of intoxication.
The electrocardiogram may reveal atrial standstill, nodal rhythm,
prolonged intraventricular conduction time, and progressive
bradycardia leading to ventricular fibrillation and / or arrest.

Overdose Treatment
Treatment of Lariago (Generic Chloroquine Phosphate tablets)
overdose is symptomatic and must be prompt with immediate
evacuation of the stomach by emesis(at home, before transportation
to the hospital) or gastric lavage until the stomach is completely
emptied.
In case finely powdered, activated charcoal is introduced by stomach
tube, after lavage, and within 30 minutes after ingestion of the
antimalarial, it may inhibit further intestinal absorption of the drug.
To be effective, the dose of activated charcoal should be at least five
times the estimated dose of Chloroquine (Lariago tablets) ingested.

Chloroquine Phosphate (Lariago tablets) During Pregnancy
Chloroquine Phosphate (Lariago tablets) has been classified by the US
FDA as Pregnancy Category: Not formally assigned to a Pregnancy
Category.
Radioactively tagged chloroquine administered intraveneously to
pregnant pigmented CBA mice passed rapidly across the placenta and
accumulated selectively in the melanin structures of the fetal eyes.
Usage of Chloroquine Phosphate (Lariago tablets) during pregnancy
should be avoided except in the prophylaxis or treatment of malaria
when the benefit outweighs the potential risk to the fetus.
There are no adequate and well-controlled studies evaluating the
safety and efficacy of chloroquine in pregnant women.

For more details on
Lariago Tablets click here
Lariago (Generic Chloroquine Phosphate tablets) by
IPCA Laboratories Limited, India.

Lariago (Generic Chloroquine Tablets)

More Related Content

What's hot

Similar to Lariago (Generic Chloroquine Tablets)

More from Clearsky Pharmacy

Recently uploaded

Lariago (Generic Chloroquine Tablets)